JP2023524819A - てんかんを治療するための組成物及び方法 - Google Patents

てんかんを治療するための組成物及び方法 Download PDF

Info

Publication number
JP2023524819A
JP2023524819A JP2022567591A JP2022567591A JP2023524819A JP 2023524819 A JP2023524819 A JP 2023524819A JP 2022567591 A JP2022567591 A JP 2022567591A JP 2022567591 A JP2022567591 A JP 2022567591A JP 2023524819 A JP2023524819 A JP 2023524819A
Authority
JP
Japan
Prior art keywords
antibody
mice
mtbi
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022567591A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524819A5 (enExample
Inventor
ティー． パズ，ジャンヌ
サンカラナラヤナン，セテュ
イェドノック，テッド
Original Assignee
ザ ジェイ． デヴィッド グラッドストーン インスティテューツ， ア テスタメンタリー トラスト エスタブリッシュド アンダー ザ ウィル オブ ジェイ． デヴィッド グラッドストーン
アネクソン，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ジェイ． デヴィッド グラッドストーン インスティテューツ， ア テスタメンタリー トラスト エスタブリッシュド アンダー ザ ウィル オブ ジェイ． デヴィッド グラッドストーン, アネクソン，インコーポレーテッド filed Critical ザ ジェイ． デヴィッド グラッドストーン インスティテューツ， ア テスタメンタリー トラスト エスタブリッシュド アンダー ザ ウィル オブ ジェイ． デヴィッド グラッドストーン
Publication of JP2023524819A publication Critical patent/JP2023524819A/ja
Publication of JP2023524819A5 publication Critical patent/JP2023524819A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2857—Seizure disorders; Epilepsy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022567591A 2020-05-05 2021-05-05 てんかんを治療するための組成物及び方法 Pending JP2023524819A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063020245P 2020-05-05 2020-05-05
US63/020,245 2020-05-05
PCT/US2021/030930 WO2021242493A2 (en) 2020-05-05 2021-05-05 Compositions and methods for treating epilepsy

Publications (2)

Publication Number Publication Date
JP2023524819A true JP2023524819A (ja) 2023-06-13
JP2023524819A5 JP2023524819A5 (enExample) 2024-05-15

Family

ID=78745740

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022567591A Pending JP2023524819A (ja) 2020-05-05 2021-05-05 てんかんを治療するための組成物及び方法

Country Status (8)

Country Link
US (1) US20240034775A1 (enExample)
EP (1) EP4146276A4 (enExample)
JP (1) JP2023524819A (enExample)
CN (1) CN115996752B (enExample)
AU (1) AU2021278819A1 (enExample)
CA (1) CA3177879A1 (enExample)
MX (1) MX2022013927A (enExample)
WO (1) WO2021242493A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201510316UA (en) 2013-07-09 2016-01-28 Annexon Inc Anti-complement factor c1q antibodies and uses thereof
US12486322B2 (en) * 2021-12-13 2025-12-02 Annexon, Inc. Anti-complement factor C1q antibodies with single binding arms and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018501813A (ja) * 2014-11-05 2018-01-25 アネクソン，インコーポレーテッド ヒト化抗補体因子Ｃ１ｑ抗体及びその使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2912396T3 (es) * 2012-11-02 2022-05-25 Bioverativ Usa Inc Anticuerpos anti-C1s del complemento y uso de los mismos
SG11201510316UA (en) * 2013-07-09 2016-01-28 Annexon Inc Anti-complement factor c1q antibodies and uses thereof
JP6779876B2 (ja) * 2014-11-19 2020-11-04 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体抗体及びその使用方法
IL309260B2 (en) * 2015-07-24 2025-01-01 Gliknik Inc Fusion proteins of human protein fragments to create ordered multimeric immunoglobulin FC preparations with enhanced complement binding
FI3380518T3 (fi) * 2015-11-24 2026-05-29 Annexon Inc Antikomplementtitekijä-C1Q:n Fab-fragmentteja ja niiden käyttöjä
US20190161535A1 (en) * 2016-05-09 2019-05-30 Annexon, Inc. Compositions and methods for treating spinal muscular atrophy
EP3487531A4 (en) * 2016-07-19 2020-03-25 Annexon, Inc. TREATMENT OF FRONTO-TEMPORAL DEMENTIA
CN112867394B9 (zh) * 2018-06-04 2024-12-06 马萨诸塞州渤健公司 具有降低的效应功能的抗vla-4抗体
MX2021004819A (es) * 2018-11-02 2021-06-08 Annexon Inc Composiciones y metodos para tratar lesiones cerebrales.
WO2020124013A1 (en) * 2018-12-13 2020-06-18 Gryphon Bio, Inc. Combinatorial temporal biomarkers and precision medicines with detection and treatment methods for use in neuro injury, neuro disease, and neuro repair

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018501813A (ja) * 2014-11-05 2018-01-25 アネクソン，インコーポレーテッド ヒト化抗補体因子Ｃ１ｑ抗体及びその使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AES ABSTRACT DATABASE, vol. 1.001, JPN6025049566, 2019, ISSN: 0005743309 *
NEUROBIOL. DIS., vol. 76, JPN6025021981, 2015, pages 87 - 97, ISSN: 0005609007 *
PROC. NATL. ACAD. SCI., vol. 107, no. 17, JPN6025021980, 2010, pages 7975 - 7980, ISSN: 0005609006 *

Also Published As

Publication number Publication date
CN115996752A (zh) 2023-04-21
WO2021242493A2 (en) 2021-12-02
CN115996752B (zh) 2025-04-01
AU2021278819A1 (en) 2022-11-24
EP4146276A4 (en) 2024-08-14
CA3177879A1 (en) 2021-12-02
EP4146276A2 (en) 2023-03-15
WO2021242493A3 (en) 2022-06-09
US20240034775A1 (en) 2024-02-01
MX2022013927A (es) 2022-11-30

Similar Documents

Publication Publication Date Title
RU2727911C2 (ru) Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения
JP7499760B2 (ja) 脳損傷を治療するための組成物及び方法
AU2017202957B2 (en) Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease
JP2019501132A (ja) 抗補体因子Ｃ１ｑ Ｆａｂ断片及びその使用
JP2019514994A (ja) 脊髄性筋萎縮症を治療するための組成物及び方法
AU2017299579A1 (en) Compositions and methods for treating frontotemporal dementia
JP2022551751A (ja) 血液障害を処置するための組成物及び方法
WO2013158748A1 (en) Human antibodies and specific binding sequences thereof for use in stroke and ischemia or ischemic conditions
CN115996752B (zh) 用于治疗癫痫的组合物和方法
HK40092865B (en) Compositions and methods for treating epilepsy
HK40092865A (en) Compositions and methods for treating epilepsy
HK1188731B (en) Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease
HK1188731A (en) Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230105

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20230105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240501

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240501

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250902

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260302

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260519